Revised SPC: Vosevi (sofosbuvir, velpatasvir and voxilaprevir) 400mg/100mg/100mg film coated tablets

Section 4.8 has been updated to include new safety information on rash and angioedema following a cumulative review of hypersensitivity with Epclusa (sofosbuvir, velpatasvir) and Vosevi, prompted by routine pharmacovigilance and signal detection activities.

electronic Medicines compendium